ArticleMedicine2015

KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.

Jeong Won Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.